Regular Session 2017-2018 Senate Bill 0668 P.N. 2001

PRIOR PRINTER'S NOS. 787, 1830

PRINTER'S NO. 2001

THE GENERAL ASSEMBLY OF PENNSYLVANIA

SENATE BILL

No.

668

Session of

2017

INTRODUCED BY GORDNER, FOLMER, BAKER, YUDICHAK, WHITE,

HUTCHINSON, STEFANO, SCARNATI, BREWSTER, RAFFERTY AND AUMENT,

MAY 4, 2017

AS AMENDED ON THIRD CONSIDERATION, SEPTEMBER 24, 2018

AN ACT

Amending the act of June 6, 1980 (P.L.197, No.57), entitled "An

act regulating the licensure and practice of optometry,

making repeals and providing penalties," further providing

for definitions; repealing provisions related to AND FOR

approval of drugs; providing for imaging test; and further

providing for exemptions and exceptions AND FOR VIOLATIONS

AND PENALTIES; AND PROVIDING FOR INSURANCE BILLING CODES.

The General Assembly of the Commonwealth of Pennsylvania

hereby enacts as follows:

Section 1. The definitions of "examination and diagnosis,"

"optometrist" and "practice of optometry" in section 2 of the

act of June 6, 1980 (P.L.197, No.57), known as the Optometric

Practice and Licensure Act, are amended to read:

Section 2. Definitions.

The following words and phrases when used in this act shall

have, unless the context clearly indicates otherwise, the

meanings given to them in this section:

* * *

"Examination and diagnosis." Any examination or diagnostic

means or method compatible with optometric education and

<--

<--<--

professional competence. The term shall encompass the use of

pharmaceutical agents approved by the Food and Drug

Administration and published in the Code of Federal Regulations

for diagnostic purposes [classified as], including, but not

limited to, miotics, mydriatics, cycloplegics, topical

anesthetics and dyes when applied topically to the eye, [which

pharmaceutical agents shall be approved by the Secretary of

Health as provided in section 4.3 and,] subject to the rules and

regulations of the board, provided however that with respect to

optometrists licensed before March 1, 1974, only such

optometrists who have satisfactorily completed a course in

pharmacology as it applies to optometry, with particular

emphasis on the topical application of diagnostic pharmaceutical

agents to the eye, approved by the board shall be permitted to

use diagnostic pharmaceutical agents topically in the practice

of optometry.

* * *

"Optometrist." Any person who, following formal and

recognized training in the art and science of optometry has

received a doctor of optometry degree from an accredited

institution and is qualified to seek or has acquired a license

to practice the profession of optometry. An optometrist shall be

identified either by "Doctor of Optometry," ["O.D.," or "Dr."

followed by "Optometrist] "O.D." or "Doctor."

"Practice of optometry."

(1) The use of any and all means or methods for the

examination, diagnosis and treatment of all conditions of the

human visual system, including all conditions of the anterior

segment of the human eye applicable to this act , . [and shall

include the examination for, and adapting and fitting of, any

20170SB0668PN2001 - 2 -

<--<--

and all kinds and types of lenses including contact lenses.]

THE TERM SHALL INCLUDE:

(I) THE EXAMINATION FOR, AND ADAPTING AND FITTING

OF, ANY AND ALL KINDS AND TYPES OF LENSES, INCLUDING

CONTACT LENSES.

(II) THE ADMINISTRATION AND PRESCRIPTION OF ALL

LEGEND AND NONLEGEND DRUGS APPROVED BY THE BOARD IN

SECTION 4.3 FOR THE TREATMENT OF DISEASES AND CONDITIONS

OF THE EYE AND ADNEXA, INCLUDING CODEINE AND HYDROCODONE

COMBINATIONS WHICH WERE RECLASSIFIED FROM SCHEDULE III TO

SCHEDULE II PRIOR TO THE EFFECTIVE DATE OF THIS

SUBPARAGRAPH. THE PRESCRIPTION OF SCHEDULE II CONTROLLED

SUBSTANCES CONTAINING CODEINE AND HYDROCODONE

COMBINATIONS MAY NOT EXCEED A 72-HOUR SUPPLY.

(III) THE REMOVAL OF SUPERFICIAL FOREIGN BODIES.

(IV) THE DRAINING OF SUPERFICIAL CYSTS OF THE

EYELIDS.

(V) EPINEPHRINE AUTO-INJECTORS FOR ANAPHYLAXIS.

(VI) THE ORDERING OF IMAGING TESTS APPROPRIATE FOR

DIAGNOSIS AND TREATMENT OF A DISEASE OR CONDITION OF THE

HUMAN VISUAL SYSTEM.

(VII) THE TREATMENT OF GLAUCOMA.

[(2) The administration and prescription of legend and

nonlegend drugs as approved by the Secretary of Health as

provided in section 4.3 for treatment of the eye, the

eyelids, the lacrimal system and the conjunctiva and the

removal of superficial foreign bodies from the ocular surface

and adnexa so long as treatment of diseases or conditions of

the visual system, other than glaucoma, as authorized under

this paragraph shall not continue beyond six weeks from the

20170SB0668PN2001 - 3 -

<--

initiation of treatment unless the prescribing optometrist

documents consultation with a licensed physician. As used in

this paragraph, the initiation of treatment may, but need

not, include the prescription or administration of

pharmaceutical agents for therapeutic purposes.

(3) The term shall not include:

(i) surgery, including, but not limited to, laser

surgery; the use of lasers for therapeutic purposes; and

the use of injections in the treatment of ocular disease;

(ii) the use of Schedule I and Schedule II

controlled substances;

(iii) treatment of systemic disease; and

(iv) the treatment of glaucoma, except that

optometrists may use all topical pharmaceutical agents in

the treatment of primary open angle glaucoma, exfoliation

glaucoma and pigmentary glaucoma.]

(4) The administration and prescription of all legend

and nonlegend drugs approved by the Commonwealth for the

treatment of ocular conditions. The term shall include the

use of nonopioid analgesic and all legend and nonlegend drugs

approved by the Food and Drug Administration and published in

the Code of Federal Regulations necessary and applicable for

the treatment of diseases and conditions of the eye and the

adnexa, including the removal of foreign bodies, drainage of

superficial cysts of the eyelids, injection for anaphylaxis

and into the upper and lower eyelids and into preplaced

portals for the delivery of pharmaceuticals for purpose of

treating diseases and conditions of the anterior segment. As

used in this paragraph, the initiation of treatment shall

include the prescription or administration of pharmaceutical

20170SB0668PN2001 - 4 -

<--

agents by any means, methods or delivery systems.

(5) (4) The term shall not include:

(i) Surgery with a scalpel or scissors, refractive

or therapeutic surgery with a laser and surgery with a

croyoprobe. An insurance procedure or billing code may

not be used to define or interpret a definition of

surgery.

(ii) Injection into the globe.

(iii) The use of Schedule I and Schedule II

controlled substances, except for the use of codeine and

hydrocodone combinations which were reclassified from

Schedule III to Schedule II prior to the effective date

of this subparagraph and any drugs approved by the

Commonwealth under this act BOARD IN SECTION 4.3 for the

treatment of ocular disease.

(IV) PROCEDURES NOT SPECIFICALLY LISTED IN PARAGRAPH

(1).

* * *

Section 2. Section 4.3 of the act is repealed AMENDED TO

READ:

[Section 4.3. Approval of drugs.

Drugs shall be approved as follows:

(1) All drugs currently approved by the Secretary of

Health and in use in the practice of optometry on the

effective date of this section shall be deemed approved under

this section.

[(2) Within 90 days of the effective date of this

section, the board shall submit a list of drugs authorized

under this act to the Secretary of Health, who, in

consultation with the Physician General, shall approve or

20170SB0668PN2001 - 5 -

<--

disapprove for good cause each drug. Upon failure of the

Secretary of Health to act within 90 days of receipt of the

list of drugs, the drugs shall be deemed approved for use

under this act.

(3) The State Board of Optometry shall provide the

Secretary of Health with lists of additional drugs for use

under this act after such drugs are approved by the Food and

Drug Administration, as published in the Code of Federal

Regulations. The Secretary of Health, in consultation with

the Physician General, shall approve or disapprove for good

cause any such drug within 90 days of the receipt of the

list. Upon failure of the Secretary of Health to act within

90 days, the drugs shall be deemed approved for use under

this act.]

Section 3. The act is amended by adding a section to read:

Section 4.4. Imaging test.

An optometrist may order an imaging test appropriate for

diagnosis and treatment of a disease or condition of the human

visual system.

(4) ON AND AFTER THE EFFECTIVE DATE OF THIS PARAGRAPH,

THE BOARD MAY APPROVE DRUGS FOR USE IN THE PRACTICE OF

OPTOMETRY FOR THE TREATMENT OF DISEASES AND CONDITIONS OF THE

EYE AND THE ADNEXA AFTER THE DRUGS ARE APPROVED BY THE FOOD

AND DRUG ADMINISTRATION, AS PUBLISHED IN THE CODE OF FEDERAL

REGULATIONS.

Section 4 3. Section 6(b) of the act is amended to read:

Section 6. Exemptions and exceptions.

* * *

(b) The board shall permit externs, who are [fourth year]

optometric students, to perform procedures and tests for the

20170SB0668PN2001 - 6 -

<--

sole purpose of instruction and experience under the direct

supervision and control of an optometrist licensed in this

Commonwealth. Nothing contained in this act shall be construed

to entitle an extern to practice optometry.

* * *

SECTION 4. SECTION 8 OF THE ACT IS AMENDED BY ADDING A

SUBSECTION TO READ:

SECTION 8. VIOLATIONS AND PENALTIES.

* * *

(A.1) IT IS UNLAWFUL FOR AN OPTOMETRIST TO ADVERTISE A

SERVICE PROHIBITED UNDER THIS ACT. A PERSON CONVICTED OF

VIOLATING THIS SUBSECTION COMMITS A SUMMARY OFFENSE AND SHALL,

FOR A FIRST OFFENSE, BE SUBJECT TO A FINE OF NOT MORE THAN $500.

FOR A SECOND OR SUBSEQUENT VIOLATION, THE BOARD MAY IMPOSE A

SUSPENSION OF THE PERSON'S LICENSE FOR UP TO 30 DAYS, IN

ADDITION TO THE FINE.

* * *

SECTION 5. THE ACT IS AMENDED BY ADDING A SECTION TO READ:

SECTION 10.1. INSURANCE BILLING CODES.

AN INSURANCE BILLING CODE MAY NOT BE USED TO DEFINE OR

INTERPRET A PROCEDURE PERFORMED BY AN OPTOMETRIST AS SURGERY.

Section 5 6. This act shall take effect in 60 days.

20170SB0668PN2001 - 7 -

<--